Skip to main content

HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved

Webinar

Watch on-demand

Join cardiologist Lars Rydén, endocrinologist Alice Cheng, and primary care practitioner Kevin Saunders who discuss the diagnosis and management of people with type 2 diabetes and shortness of breath in primary care, and how the positive findings of EMPEROR-Preserved will now shape the care of these patients. Watch now

Keep up with the latest news on HFpEF

20-12-2022 | Dapagliflozin | News

Dapagliflozin on way to EC approval for all heart failure

Click through to read more on this announcement

06-12-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.

18-11-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

Interviews on heart failure

Mikhail Kosiborod

01-11-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

Kevin Fernando

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: The implications for primary care

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

Stefan Anker

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.

Adriaan Voors

02-03-2022 | Empagliflozin | Video

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.